Comparative Pharmacology
Head-to-head clinical analysis: ELAPRASE versus KANUMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAPRASE versus KANUMA.
ELAPRASE vs KANUMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idursulfase is a recombinant form of iduronate-2-sulfatase, the enzyme deficient in Hunter syndrome (MPS II). It hydrolyzes 2-sulfate groups from the terminal iduronate sulfate glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, thereby reducing GAG accumulation in tissues.
Recombinant human lysosomal acid lipase (LAL) that catalyzes the hydrolysis of cholesteryl esters and triglycerides in lysosomes.
0.58 mg/kg IV once weekly administered over 1 hour
1 mg/kg intravenously over 4 hours once weekly.
None Documented
None Documented
Terminal half-life: 6.5–8.5 hours (mean 7.5 h) in pediatric patients; supports weekly IV dosing
Terminal elimination half-life: approximately 2–5 hours (range 1.5–7.5 hours) in patients with LAL deficiency. Clinical context: half-life supports weekly intravenous dosing.
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are reused or excreted
Primarily cleared via receptor-mediated endocytosis and lysosomal degradation; negligible renal or biliary/fecal elimination of active drug. <1% excreted unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy